Accent Microcell Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xhm0uy51v07ozzr14xexciz6.pdf

Key Takeaways


The Sigachi Tailwind

Ghanshyam Patel: “We are having almost 5 to 6 months. We have order on hands. So we are. Know any. There is any threat about this. Unique 3 phase one, and even phase two's order and business.”

Unit 3: The Margin Transformation Thesis

Phase 1: Premium excipients (CCS-led)

Phase 2: MCC scale-up

Blended margin target

Ghanshyam Patel: “Definitely, it is prudent enough to assume the PAT levels of 25% from CCS, that is, that is the basic difference between MCC and premium range of product.”

The Marquee Customer Win

Ghanshyam Patel: “I just wanted to share the good news from the accent side about the name about the company. Actually, I just don't want to reveal the name of the company, but after you can see 3 to 4 years of approval exercise, we have just received the final confirmation about the business just to start up, and the product would be microsterized cellulose, and that would be renowned and well established multinational company globally.”

Product Portfolio & Technology Shift


Financial Health & Working Capital

Ghanshyam Patel: “About, when it comes to RPT stating it to be 0 will be very, very optimistic. So we'll prefer not to comment to it.”

Market Structure & Competitive Position


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue CAGR15–20% over 3–5 years; near-term growth can be higher3–5 year horizon
Blended EBITDA margin20–22%Within next couple of years, once Phase 2 is fully operationalized or at 70% capacity
Unit 3 Phase 1 commercializationCommercial production beginsEnd of October / first week of November 2025
Unit 3 Phase 1 FY26 revenue₹70 crores (partial year)FY26
Unit 3 Phase 1 first-year utilization~60%First year post-commercialization
Unit 3 Phase 1 standalone PAT margin25%From commercialization
Unit 3 Phase 2 trial runsTrial runs commenceJuly 2026
Unit 3 Phase 2 capex₹55–60 crores (excluding land)Construction just started
Unit 3 Phase 2 first-year utilization50–55% over 9 monthsFinancial year of commissioning
Full-capacity blended PAT margin20–22% on 24,000 MTPASubject to full utilization and overhead distribution
New global customer supply“Multiple 1,000 tons” of MCCOver next couple of years
Debtor days rationalizationExpected to rationalizeOnce new MNCs are on-boarded

Key Metrics

MetricQ1 FY26
Revenue (FY25)₹265 cr, near-peak capacity utilization
EBITDA margin (FY25)~16%, with target of 20–22% in next couple of years
PAT margin target (Phase 1, Unit 3)25% for CCS product
Weighted average PAT margin target (full 24,000 MT capacity)20–22%
Company-level revenue CAGR target15–20% for next 3–5 years
Industry MCC CAGR5–6%, expected to increase by 1–1.5%
Current total capacity9,600 metric tons per annum
Unit 3 Phase 1 capacity (premium excipients)2,400 metric tons per annum, commissioning by Oct–Nov 2025
Unit 3 Phase 2 capacity (MCC)12,000 metric tons per annum, commissioning by Jul 2026
Total capacity post all expansions24,000 metric tons per annum
Export mix65% of total turnover
US exposure4–5% of total turnover
Order book5–6 months of orders on hand for Unit 3 Phase 1 and Phase 2
Long-term contracts10–15% of turnover, rest are open or spot contracts
Debtor daysOver 100 days, increased from 70–80 range in last 2 years
Global MCC market size250,000 metric tons per annum
Indian MCC market size50,000 metric tons per annum
Total capex for Unit 3 (Phase 1 + Phase 2, excluding land)₹105–110 cr
Rights issue amount~₹40 cr
Phase 2 capex₹55–60 cr, excluding land
FY25 traded volumes15% of total, own manufactured 85%
PAT margin on traded goods5–7%
Raw material inventory~2 months; finished goods inventory ~1 month
CCS price vs MCC~3.5 times MCC price
MCC export price~₹230 per kg; domestic ~₹180 per kg
Incremental realization from new premium products5–7% increase in sales of finished goods
Phase 1 expected utilization in first year~60%
Phase 2 expected utilization in first year50–55% for that financial year (9 months)
FY25 domestic revenue~₹120 cr
FY25 domestic profit~₹2 cr, 2% margin
Export geographic splitNorth & South America 55%, Asia 30–35%, Europe 8–10%, Australia 5%
FY28 full-ramp top line potential (all 3 units, current prices)~₹700 cr (per an analyst's math)